As Executive Director, James leads the IFPMA’s Global Health programme of work, developing policy, engaging with stakeholders and building partnerships across the public and private sectors. James focuses on priority disease areas including AMR, pandemic preparedness, and non-communicable diseases, to address key challenges for our companies, health stakeholders and patients.

Prior to joining the IFPMA in January 2021, James worked in a variety of roles at GSK since joining in 2005.
James has been involved in establishing multiple initiatives to address AMR, including the AMR Action Fund, the Davos Declaration, the IMI ‘New Drugs for Bad Bugs’, GARDP, and the AMR Industry Alliance, and advised the O’Neill AMR Review, the UK Government-Industry Joint TF, the WHO and the EU Commission.
James serves as Chair both of the AMR Industry Alliance and the INTREPID Alliance on antivirals and has also served on the Board of the UK Life Science Strategy and as the Vice-Chair of Business at OECD Healthcare Committee.